A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection
Public ClinicalTrials.gov record NCT01220947. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This randomized, open-label, active-controlled, parallel-group study will evaluate the sustained virological response of danoprevir boosted with low dose ritonavir in combination with Pegasys (peginterferon alfa-2a) and Copegus versus Pegasys and Copegus alone in treatment-naive patients with chronic Hepatitis C.
Study identification
- NCT ID
- NCT01220947
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 421 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2010
- Primary completion
- Nov 30, 2012
- Completion
- Nov 30, 2012
- Last update posted
- Nov 1, 2016
2010 – 2012
United States locations
- U.S. sites
- 25
- U.S. states
- 15
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | La Jolla | California | 92037-1030 | — |
| Not listed | Sacramento | California | 95817 | — |
| Not listed | San Diego | California | 92154 | — |
| Not listed | San Francisco | California | 94143 | — |
| Not listed | Aurora | Colorado | 80045 | — |
| Not listed | Orlando | Florida | 32804 | — |
| Not listed | Orlando | Florida | 32809 | — |
| Not listed | South Miami | Florida | 33143 | — |
| Not listed | Decatur | Georgia | 30033 | — |
| Not listed | Honolulu | Hawaii | 96817 | — |
| Not listed | Chicago | Illinois | 60637 | — |
| Not listed | Lutherville | Maryland | 21093 | — |
| Not listed | Detroit | Michigan | 48202-2689 | — |
| Not listed | Manhasset | New York | 11030 | — |
| Not listed | New York | New York | 10021 | — |
| Not listed | The Bronx | New York | 10468 | — |
| Not listed | Chapel Hill | North Carolina | 27599-7584 | — |
| Not listed | Fayetteville | North Carolina | 28304 | — |
| Not listed | Medford | Oregon | 97504 | — |
| Not listed | Providence | Rhode Island | 02905 | — |
| Not listed | Nashville | Tennessee | 37211 | — |
| Not listed | Houston | Texas | 77030 | — |
| Not listed | San Antonio | Texas | 78215 | — |
| Not listed | San Antonio | Texas | 78234 | — |
| Not listed | Newport News | Virginia | 23602 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 43 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01220947, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 1, 2016 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01220947 live on ClinicalTrials.gov.